Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of AP303 in Healthy Subjects
NCT05503693Phase 1Completed
- Sponsor
- Alebund Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AP-303 in autosomal dominant polycystic kidney disease (ADPKD) and diabetic kidney disease (DKD) (4 arms), sponsored by Alebund Pharmaceuticals. Primary endpoints: Single Dose and Food Effect Safety Outcome Measures, Multiple Dose Safety Outcome Measures and 15 more. Started Dec 2022; status: completed.
02
Drugs
AP-303
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05503693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503693.